Volume 24, Issue 2 (June & July 2021)                   J Arak Uni Med Sci 2021, 24(2): 196-203 | Back to browse issues page

XML Persian Abstract Print

1- Department of General Practitioner, School of Medical Shahid Babaee, Qazvin University of Medical Science, Qazvin, Iran.
2- Department of Pathobiology, Shahid Babaei School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran. , qums@gmail.com
3- Department of Parasitology, Shahid Babaei School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.
Abstract:   (1575 Views)

Background and Aim: Ovarian cancer is among the most common cancers in women worldwide. CA125 is the most frequent biomarker used in the screening for ovarian cancer. CA125 has no high sensitivity and specificity as a screening test in the medical community; however, because of being simple and noninvasive, it is almost always requested for evaluation and ruling out cancer. It plays an important role in the treatment and post-treatment process, the prediction of prognosis, and the relapse of the disease. The present study aimed to determine the relationship between a high level of CA125 tumor marker and ovarian cancer by detecting spesivity, sensivity, positive and negative predictive values.
Methods & Materials: In this cross-sectional study, all cases undergoing CA125 test in Velayat Hospital in 
2017-1028 were evaluated for having ovarian cancer. In addition, the CA125 level was compared between healthy individuals and patients with ovarian cancer. Finally, the obtained data were analyzed using SPSS.
Ethical Considerations: The present study was approved by the Qazvin University of Medical Sciences (Ethics Code: IR.QUMS.REC.1396.316).
Results: In this study, 35.3% of the study participants received a definite diagnosis of ovarian cancer. Generally, CA125 values were negative in 41.8% and positive in.58.2% of the study subjects. The sensitivity of the test was measured as 80.1%, the specivity as 53.6%, the positive predictive value equaled 48.4%, and the negative predictive value was measured as 83%. There was a significant relationship between age and the presence of ovarian cancer, and serum CA125 levels.
Conclusion: The present study suggested that age and the serum level of CA125 were statistically significant. Finally, CA125 levels were significantly related to ovarian cancer. It provided moderate specivity and specivity as well as low positive predictive value and high negative predictive value as a tumor marker; it is valuable for ruling out of tumor but not appropriate as a screening test.

Full-Text [PDF 3264 kb]   (646 Downloads) |   |   Full-Text (HTML)  (2525 Views)  
Type of Study: Original Atricle | Subject: Internal
Received: 2019/10/11 | Accepted: 2021/04/19

1. Noori-Daloii M R, Rashvand Z. Molecular Genetics and Gene Therapy in Ovarian Cancer. Horizon Med Sci . 2010; 16 (3) :5-19
2. Marjani M. Epidemiology and risk factors of ovarian cancer. NAIGO 2010;5(3):67-73.
3. Chavoshi S, haidari kashl S, rezaee tavirani M, ebrahimi M, etedali A, Raessodati R, et al . Tumor Markers at a Glance. SJIMU. 2013; 21 (6) :143-159
4. Sundar S, Neal RD, Kehoe S. Diagnosis of ovarian cancer. BMJ. 2015 Sep 1;351:h4443. [DOI:10.1136/bmj.h4443]
5. Nolen BM, Lokshin AE. Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Mol Diagn Ther J.2013 Jun;17(3):139-46. [DOI:10.1007/s40291-013-0027-6]
6. Duraisamy S, Ramasamy S, Kharbanda S, Kufe D "Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16". Gene J May 2012; 373: 28-34. [DOI:10.1016/j.gene.2005.12.021]
7. Suh KS, Park SW, Castro A, Patel H, Blake P, Goy A. "Ovarian cancer biomarkers for molecular biosensors and translational medicine". Expert Review of Molecular Diagnostics. Nov 2010;10 (8): 1069-83 [DOI:10.1586/erm.10.87]
8. Bast RC, Klug TL, St John E, Jenison E, Niloff JM "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer". The New England Journal of Medicine.Oct 2013;chapter 2 pp98.
9. Göcze P, Vahrson H.Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies). Orvosi Hetilap J(in Hungarian). Apr 2012;10(5):35-45
10. Lycke M, Kristjansdottir B, Sundfeldt K. A multicenter clini(cal trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol J. 2018 Aug 24.;pii: S0090-8258(18)31155-7. [DOI:10.1016/j.ygyno.2018.08.025]
11. Jafari Shobeiri M, Parizad Nasirkandy M, Nazari F, Ouladsahebmadarek E, Sayyah-Melli M, Mostafa Gharabaghi P, et al. Diagnostic Value of HE4, CA125 and Risk of Ovarian Malignancy Algorithm in Detecting Ovarian Cancer. IJWHR 2015; 3: 208-211 [DOI:10.15296/ijwhr.2015.43]
12. Yousefi Z, Hasanzadeh Mofrad M, Kazemianfar Z, Ayatollahi H, Tavassoli F, Beyranvandi M, et al. Comparison of Serum Levels of HSP70 and CA125 in Patients with Epithelial Ovarian Cancer and Patients with Benign Ovarian Masses. The Iranian Journal of Obstetrics, Gynecology and Infertility, 2014; 17(101): 1-5.
13. Pallavi Anand, Ipsita Choudhury A case study of assessment of CA-125 levels in the rural population of Kanpur. JMR 2015;1(5):139-141.
14. Arab M, Maktabi M, Zham H, Kimiaei P, Davalo S. Is Ovarian Mass Malignancy Prediction Accuracy Increased by Adding Serum CA125 Measurement to Sonographic Findings?. Avicenna J Clin Med. 2012; 18 (4) :37-40
15. Bashizadeh-Fakhar H, Rezaie-Tavirani M, Zali H, Faraji R, Kazem Nejad E, et al. The Diagnostic Value of Serum CEA, CA-125, and ROMA Index in Low-Grade Serous Ovarian Cancer, Int J Cancer Manag. 2018 ;11(5):e63397. [DOI:10.5812/ijcm.63397]
16. Yousefi Z, Homaei F. Risk Factors and Factors in Determining the Prognosis of Ovarian Cancer. JMCI 2006;24(3):279-88.
17. Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. J Ovarian Res. 2009 Oct 9;2:13. [DOI:10.1186/1757-2215-2-13]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.